CPI-0610 is primarily investigated for its potential in treating various types of cancers, particularly those involving abnormal gene expression and uncontrolled cell proliferation. It functions as a BET inhibitor, targeting bromodomain and extra-terminal (BET) proteins, which play a critical role in regulating gene transcription. By inhibiting these proteins, CPI-0610 disrupts the expression of oncogenes and other factors that drive tumor growth and survival. This mechanism makes it a promising candidate for use in hematologic malignancies such as myelofibrosis, as well as solid tumors. Additionally, it is being explored in combination therapies to enhance the efficacy of other anticancer agents, potentially overcoming resistance mechanisms and improving patient outcomes. Its application is currently in clinical trials, focusing on safety, tolerability, and therapeutic effectiveness in cancer treatment.